| 000 | 01592 a2200421 4500 | ||
|---|---|---|---|
| 005 | 20250513230017.0 | ||
| 264 | 0 | _c20010301 | |
| 008 | 200103s 0 0 eng d | ||
| 022 | _a0724-8741 | ||
| 024 | 7 |
_a10.1023/a:1007568811691 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKatoh, M | |
| 245 | 0 | 0 |
_aInhibitory potencies of 1,4-dihydropyridine calcium antagonists to P-glycoprotein-mediated transport: comparison with the effects on CYP3A4. _h[electronic resource] |
| 260 |
_bPharmaceutical research _cOct 2000 |
||
| 300 |
_a1189-97 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article | ||
| 650 | 0 | 4 |
_aATP Binding Cassette Transporter, Subfamily B, Member 1 _xantagonists & inhibitors |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aBiological Transport _xdrug effects |
| 650 | 0 | 4 |
_aCalcium Channel Blockers _xpharmacology |
| 650 | 0 | 4 | _aCell Line |
| 650 | 0 | 4 | _aCytochrome P-450 CYP3A |
| 650 | 0 | 4 | _aCytochrome P-450 Enzyme Inhibitors |
| 650 | 0 | 4 |
_aCytochrome P-450 Enzyme System _xmetabolism |
| 650 | 0 | 4 |
_aDaunorubicin _xpharmacokinetics |
| 650 | 0 | 4 |
_aDigoxin _xpharmacokinetics |
| 650 | 0 | 4 |
_aDihydropyridines _xpharmacology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aMixed Function Oxygenases _xantagonists & inhibitors |
| 650 | 0 | 4 | _aSubstrate Specificity |
| 650 | 0 | 4 | _aTransfection |
| 650 | 0 | 4 | _aTritium |
| 700 | 1 | _aNakajima, M | |
| 700 | 1 | _aYamazaki, H | |
| 700 | 1 | _aYokoi, T | |
| 773 | 0 |
_tPharmaceutical research _gvol. 17 _gno. 10 _gp. 1189-97 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1023/a:1007568811691 _zAvailable from publisher's website |
| 999 |
_c11085219 _d11085219 |
||